Journal of veterinary internal medicine · 2021
Evaluation of compounded trilostane packets for dogs with naturally occurring hyperadrenocorticism.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nam Sookin, Kim Tae-Won, Song Kun-Ho, Feldman Edward C, Seo Kyoung-Won
Аннотация
BACKGROUND: Dogs treated for naturally occurring hyperadrenocorticism (NOH) in Korea often appear to require higher doses of trilostane than recommended by authors in the United States, Europe, or the United Kingdom. This phenomenon may be related to compounding trilostane into packets, which is a common practice among veterinary clinics in Korea.
OBJECTIVE: Analyze packets filled by hand and others filled using a semi-automatic packing device for accuracy of trilostane strength.
ANIMALS: Medication packets prepared for 3 dogs with preexisting prescriptions for NOH were analyzed.
METHOD: A trilostane assay was developed for analysis. Trilostane (Vetoryl) capsules were used as clinical controls. Forty-four medication packets containing trilostane (Vetoryl), prepared by 3 clinicians for 3 dogs with NOH were analyzed.
RESULTS: Of 44 trilostane-containing packets, only 40.9% (18 packets) had acceptable strength of trilostane.
CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be aware that compounding trilostane into packets fails to consistently provide measured amounts of trilostane, potentially interfering with response to treatment for NOH in dogs.
OBJECTIVE: Analyze packets filled by hand and others filled using a semi-automatic packing device for accuracy of trilostane strength.
ANIMALS: Medication packets prepared for 3 dogs with preexisting prescriptions for NOH were analyzed.
METHOD: A trilostane assay was developed for analysis. Trilostane (Vetoryl) capsules were used as clinical controls. Forty-four medication packets containing trilostane (Vetoryl), prepared by 3 clinicians for 3 dogs with NOH were analyzed.
RESULTS: Of 44 trilostane-containing packets, only 40.9% (18 packets) had acceptable strength of trilostane.
CONCLUSIONS AND CLINICAL IMPORTANCE: Clinicians should be aware that compounding trilostane into packets fails to consistently provide measured amounts of trilostane, potentially interfering with response to treatment for NOH in dogs.